TIGAN Drug Patent Profile
✉ Email this page to a colleague
When do Tigan patents expire, and what generic alternatives are available?
Tigan is a drug marketed by King Pharms Llc and Par Sterile Products and is included in two NDAs.
The generic ingredient in TIGAN is trimethobenzamide hydrochloride. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the trimethobenzamide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tigan
A generic version of TIGAN was approved as trimethobenzamide hydrochloride by LUPIN on August 20th, 2003.
Summary for TIGAN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 68 |
Patent Applications: | 422 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TIGAN |
What excipients (inactive ingredients) are in TIGAN? | TIGAN excipients list |
DailyMed Link: | TIGAN at DailyMed |
Pharmacology for TIGAN
Drug Class | Antiemetic |
Physiological Effect | Emesis Suppression |
Anatomical Therapeutic Chemical (ATC) Classes for TIGAN
US Patents and Regulatory Information for TIGAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
King Pharms Llc | TIGAN | trimethobenzamide hydrochloride | CAPSULE;ORAL | 017531-006 | Dec 13, 2001 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Par Sterile Products | TIGAN | trimethobenzamide hydrochloride | INJECTABLE;INJECTION | 017530-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |